Nedaplatin

Drug Overview

Nedaplatin (also known as Aqupla or NSC-375101D) is a second-generation cisplatin analogue and a member of the platinum-based chemotherapy family. It was specifically developed to provide anti-tumor efficacy comparable to cisplatin but with a significantly improved safety profile, particularly regarding kidney and gastrointestinal toxicity.

In the clinical landscape of March 2026, nedaplatin is recognized as a staple in Asian oncology, particularly in Japan, where it was originally developed by Shionogi & Co. It contains a unique ring structure where glycolate is bound to the platinum ion. Like other platinum compounds, it acts as a “DNA-damaging” agent, but its chemical structure allows it to be administered with less intensive hydration than is required for cisplatin.

• Generic Name: Nedaplatin.
• Brand Name: Aqupla.
• Drug Class: Platinum-based Antineoplastic Agent; Radiosensitizer.
• Mechanism: Formation of DNA cross-links (intrastrand and interstrand), leading to apoptosis.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational/Orphan Status. As of March 2026, nedaplatin is not FDA-approved for general commercial use in the United States. It has been granted Orphan Drug Designation by the FDA for the treatment of esophageal cancer and small cell lung cancer (SCLC), allowing for specialized clinical trial access. It is fully approved and widely used in Japan.

What Is It and How Does It Work? (Mechanism of Action)

Nedaplatin exerts its anti-cancer effects by attacking the cell’s genetic blueprint, preventing cancer cells from dividing and thriving.

1. DNA Cross-linking

Once nedaplatin enters a cancer cell, it undergoes hydrolysis to become its active form.

• Targeting Nucleophiles: The active platinum complex binds to nucleophilic groups on DNA, specifically at the guanine and adenine bases.
• The “Structural Lock”: It forms physical bridges (cross-links) between DNA strands. These cross-links are like “kinks” in a zipper that prevent the DNA from being unzipped and copied during cell division.

2. Induction of Apoptosis

When the cell’s internal machinery detects that its DNA is severely damaged and cannot be repaired, it triggers a self-destruct sequence.

• Mitotic Catastrophe: Because the cell cannot complete division (mitosis) with “locked” DNA, it enters programmed cell death (apoptosis).
• Radiosensitization: Nedaplatin also makes cells more sensitive to radiation therapy by inhibiting the repair of radiation-induced DNA breaks, a property widely used in treating head, neck, and esophageal cancers.

3. Reduced Toxicity Mechanism

The glycolate “leaving group” in nedaplatin is more stable than the chloride groups in cisplatin. This leads to slower activation, which is believed to be the reason for its lower nephrotoxicity (kidney damage) and lower emetogenicity (nausea and vomiting).

Clinical Indications and Status (2026)

While its primary use is in Japan, nedaplatin is a major subject of global research for several difficult-to-treat malignancies:

• Esophageal Squamous Cell Carcinoma (ESCC): Often used in “triplet” regimens with docetaxel and 5-fluorouracil (DNF). In 2025–2026, research has highlighted its success in neoadjuvant (pre-surgery) settings.
• Non-Small Cell Lung Cancer (NSCLC): Particularly effective for the squamous cell subtype. Clinical trials (like WJOG5208L) have shown it can extend overall survival when combined with docetaxel compared to standard cisplatin/docetaxel.
• Head and Neck Cancers: Used frequently in concurrent chemoradiotherapy (CCRT) for nasopharyngeal and hypopharyngeal cancers.
• Other Cancers: Investigated in ovarian, cervical, bladder, and testicular cancers, especially for patients who cannot tolerate the high kidney-stress of cisplatin.

Dosage and Administration Protocols

Dosing of nedaplatin is typically determined by Body Surface Area (BSA) and must be adjusted carefully based on the patient’s kidney function (creatinine clearance).

Clinical Efficacy and Research Results

As of early 2026, recent comparative studies have reaffirmed nedaplatin’s place in modern oncology:

• Lung Cancer Superiority: In a randomized study of advanced squamous NSCLC, the nedaplatin group achieved an Overall Response Rate (ORR) of 48.6%, compared to 35.1% in the cisplatin group, with significantly longer survival times.
• Esophageal Cancer Breakthroughs: The 2025 “Frontiers in Oncology” report indicated that nedaplatin-based neoadjuvant therapy resulted in a 82.1% complete response rate in certain esophageal cancer cohorts, with a superior safety profile regarding radiotherapy-associated esophagitis.
• Palliative Success: For rare cancers like adenoid cystic carcinoma (ACC), nedaplatin has shown promise in reducing tumor markers (LDH) and providing palliative relief even when other therapies fail.

Safety Profile and Side Effects

The primary advantage of nedaplatin is what it doesn’t do as severely as cisplatin (kidney damage), but it has its own “dose-limiting” toxicity.

Common Side Effects (>20%):

• Hematologic Toxicity (Myelosuppression): This is the most significant concern.
  • Thrombocytopenia: A severe drop in platelets is the dose-limiting toxicity for nedaplatin.
  • Leukopenia/Neutropenia: A drop in white blood cells, increasing infection risk.
• Gastrointestinal: Nausea, vomiting, and loss of appetite, though generally moderate rather than severe.
• Fatigue: General tiredness experienced by nearly all patients undergoing platinum therapy.

Serious Risks:

• Nephrotoxicity: While lower than cisplatin, kidney damage can still occur, especially in patients with pre-existing kidney issues.
• Ototoxicity: Hearing loss or ringing in the ears (tinnitus), though less frequent than with other platinum drugs.
• Secondary Malignancies: As a DNA-damaging agent, there is a very rare long-term risk of developing other cancers years later.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, nedaplatin is a critical tool for studying “Renal Papillary Injury.” Researchers are using nedaplatin to study the deregulation of genes like cytokeratin 14 and 19 to find ways to “re-grow” kidney tubule cells after chemotherapy damage. In 2026, there is also intense focus on “Immuno-chemotherapy.” Scientists are investigating if nedaplatin can “prime” the tumor environment to make it more receptive to PD-1 inhibitors by increasing the number of mutations (tumor mutational burden) that the immune system can recognize.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Creatinine Clearance Test: Mandatory to determine if the patient’s kidneys can handle the drug.
• Baseline CBC: To check platelet and white blood cell levels.

“Do’s and Don’ts” List:

• DO report any unusual bruising or bleeding (like from the gums or nose) immediately, as this is a sign of low platelets.
• DO maintain moderate hydration (about 1.5–2 liters of water) on the day of and the day after treatment.
• DON’T ignore a fever higher than 38°C (100.4°F); this could be a sign of “febrile neutropenia” and requires emergency care.
• DON’T consume alcohol or herbal supplements that might stress the kidneys or liver during the 48 hours surrounding your infusion.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Nedaplatin is an investigational drug in the U.S. and a prescription-only chemotherapy in other regions. Always consult with a qualified oncologist regarding your specific diagnosis and the suitability of platinum-based therapy.